MedTrace Logo

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

NCT00419445 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2010-09-10

Study results available
· View outcomes & findings →

Summary

This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

GTS21/Placebo

Sponsors & Collaborators

  • CoMentis

    lead INDUSTRY

Principal Investigators

  • Carl Grove · CoMentis (formerly Athenagen)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419445 on ClinicalTrials.gov